Table 1 Clinical manifestations of anti-NMDAR encephalitis patients with and without SE
|  | non-SE (n = 44) | SE (n = 21) | p-Value |
|---|---|---|---|
Age (years) | 29.45 ± 11.75 | 26.48 ± 9.44 | 0.314 |
Gender (female) (n, %) | 25(56.82%) | 11(52.38%) | 0.736 |
Symptom (n, %) | |||
 Psychiatric symptoms | 38(86.36%) | 19(90.48%) | 0.699 |
 Speech disturbances | 10(22.73%) | 2(9.52%) | 0.309 |
 Memory deficits | 23(52.27%) | 6(28.57%) | 0.072 |
 Movement disorders | 12(27.27%) | 10(47.62%) | 0.105 |
 Loss of consciousness | 17(38.64%) | 11(52.38%) | 0.295 |
 Central hypoventilation | 7(15.91%) | 5(23.81%) | 0.443 |
Time from first symptom to diagnosis (median, days) | 30 | 15 | 0.026 |
 ALB, g/L | 40.21 ± 5.10 | 39.79 ± 6.79 | 0.785 |
 TBILI, μmol/L | 10.19 ± 4.73 | 12.36 ± 13.49 | 0.365 |
 UA, μmol/L | 288.82 ± 91.32 | 222.68 ± 77.53 | 0.008 |
 Cr, μmol/L | 61.99 ± 19.19 | 64.00 ± 20.73 | 0.702 |
 CHOL, mmol/L | 4.04 ± 0.97 | 4.14 ± 0.74 | 0.295 |
 LDL-C, mmol/L | 2.92 ± 0.92 | 2.75 ± 0.64 | 0.464 |
 HDL-C, mmol/L | 1.33 ± 0.56 | 0.94 ± 0.25 | 0.000 |
 CRP, mg/L | 3.59 ± 4.03 | 7.96 ± 8.95 | 0.069 |
 Brain MRI abnormality | 21(47.73%) | 6(28.57%) | 0.143 |
 Teratoma presence | 8(18.18%) | 4(19.05%) | 1.000 |
 Brain MRI abnormality | 21(47.73%) | 6(28.57%) | 0.143 |
 Teratoma presence | 8(18.18%) | 4(19.05%) | 1.000 |
 Second-line immunotherapy | 9(20.45%) | 4(19.05%) | 1.000 |
 Long-term immunosuppression | 8(18.18%) | 5(23.81%) | 0.596 |